Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

ALLO Allogene Therapeutics

Watchlist
9.485
+0.115+1.23%
Trading Session 12/02 15:54 ET
High
9.550
Open
9.260
Turnover
11.01M
Low
8.935
Pre Close
9.370
Volume
1.18M
Market Cap
1.37B
P/E(TTM)
Loss
52wk High
19.110
Shares
144.21M
P/E(Static)
Loss
52wk Low
6.425
Float Cap
776.34M
Bid/Ask %
0.00%
Historical High
55.000
Shs Float
81.85M
Volume Ratio
0.48
Historical Low
6.425
Dividend TTM
--
Div Yield TTM
--
P/B
1.85
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.44%
Amplitude
6.56%
Avg Price
9.354
Lot Size
1
Float Cap
776.34M
Bid/Ask %
0.00%
Historical High
55.000
Shs Float
81.85M
Volume Ratio
0.48
Historical Low
6.425
Dividend TTM
--
P/B
1.85
Dividend LFY
--
Turnover Ratio
1.44%
Amplitude
6.56%
Avg Price
9.354
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
CEO: Dr. David D. Chang, M.D.,PhD
Market: NASDAQ
Listing Date: 10/11/2018
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist